Skip to main content
. Author manuscript; available in PMC: 2010 Mar 1.
Published in final edited form as: Oral Dis. 2008 Nov 11;15(2):121–132. doi: 10.1111/j.1601-0825.2008.01495.x

Table 3.

Selected Trials of Induction chemotherapy

Study Patient characteristics Treatment OS DM Comments
EORTC 24891 (Lefebvre) 194 pts
Stage II-IV
HP		 surgery + post-op RT (S+RT) vs. cisplatin/5FU→RT (IND) 5 yr OS
30% (S+RT)
35% (IND)		 5 yr DM
36% (S+RT)
25%(IND)* 		Chemotherapy arm had 5 yr larynx preservation of 36%
GETTEC trial (Domenge) 318 pts
Stage T2-4N0-2b
OP		 surgery ± post-op RT (S+RT) or RT alone vs. cisplatin/5FU→surgery, RT (IND) Median OS
3.3 yrs (S+RT or RT)
5.1 yrs (IND)* 		NR Less local recurrence in induction chemotherapy group
VA larynx 332 pts
Stage III/IV larynx		 surgery + post-op RT (S+RT) vs. cisplatin/5FU →RT (IND) 2 yr OS
68% (S+RT)
68% (IND)		 NR NA

OS= overall survival, DM= distant metastases, HP = hypopharynx, OP = oropharynx, 5FU = 5-fluorouracil, post-op = post-operative, IND = induction chemotherapy, S= surgery, RT= radiation treatment,

*

= p≤0.05, NR = not reported